



Viral encephalitis with secondary *Acinetobacter baumannii* meningitis- a diagnostic challenge

Dr Kshitija Valvaikar¹, Dr Masood Mujawar²

1. MBBS, junior resident of medicine department, Goa medical college

2. MBBS, junior resident of medicine department, Goa medical college

Corresponding author: Dr Kshitija Valvaikar

Submitted: 10-12-2021

Revised: 22-12-2021

Accepted: 25-12-2021

I. INTRODUCTION

Meningitis refers to inflammation of the meninges whereas the term encephalitis involves inflammation of the brain parenchyma with evidence of meningeal involvement with signs and symptoms of focal or diffuse neurological deficit. Herpes simplex virus is the most common virus causing viral encephalitis. The incidence of viral encephalitis is 3.5 to 7.5 per 100,000 people, with the highest incidence in the young and elderly⁽⁴⁾

HSV encephalitis usually involves frontal and temporal lobe hence is associated with behavioural, psychiatric disturbances, memory deficits and aphasia.

Acinetobacter, a gram-negative coccobacillus, is strictly aerobic and non-fermentative; and is well documented as a nosocomial pathogen. It is an opportunistic pathogen found on skin and respiratory and GI tract of humans. The organism exhibits diverse mechanisms of resistance, and this has led to the emergence of strains that are resistant to all commercially available antibiotics.¹

Acinetobacter baumannii is one of the ESCAPE organisms, which refers to a group of health care-associated organisms that have the potential for substantial antimicrobial resistance. It is important to note that carbapenem-resistant *A. baumannii* is one of the critical-priority pathogens on the World Health Organization priority list of antibiotic-resistant bacteria for effective drug development.

There is mounting evidence that *A. baumannii* can no longer be exclusively considered a nosocomial pathogen, and is capable of causing profound clinical disease in the absence of traditional nosocomial risk factors.

Acinetobacter meningitis usually reported in post neurosurgical patients and those with an External Ventricular Device (EVD) and is typically characterised by fever and change in consciousness. Meningeal signs, focal neurological signs, and seizure are found in a minority of patients. Increased CSF white blood cell counts

(ranging from 100 to several thousand cells per μL) are typical. However, there are also reports of cases of true infection that have no CSF white blood cells. Typically, 75–100% of the white blood cells are polymorphonuclear cells. CSF protein is almost always raised, most typically being between 150 mg/L and 200 mg/L. CSF glucose may be normal or depressed.

All-cause mortality from *Acinetobacter meningitis* ranges from 15% to 71%. Highest mortality rates have been observed in neonates and in units where large numbers of carbapenem-resistant *Acinetobacter* were observed.

II. CASE REPORT


A 66 years old male, known case of Diabetes mellitus and Hypertension for the last 10 years on regular treatment, with no past history of neurosurgery or head injury and no past history of hospitalisation, presented to the emergency department with history of one episode of generalised tonic clonic convulsions, headache, vomiting and altered sensorium in the form of decreased verbal output since one day. There was no history of fever at admission. Initial examination revealed that the patient was afebrile, pulse rate was 80 beats/min, BP was 230/140 mmHg, respiratory rate was 18 breaths/min. The patient was conscious, confused and did not have any other neurological deficit. CT Brain at admission was normal. A provisional diagnosis of hypertensive encephalopathy was made and patient was started on nitroglycerine infusion and tablet amlodipine and injectable levetiracetam.

Even though the blood pressure was normalised, the patient's sensorium did not improve. The patient was found to have global aphasia, hence a repeat CT Brain was performed with the presumptive diagnosis of an ischaemic cerebrovascular accident in mind. However, only a lacunar infarct in the right thalamus was noted. The patient during the course of hospital stay was found




to have high fever spikes. Blood investigations performed on admission showed a white blood cell count 15,300 cells/cmm (N-69% L-17%), haemoglobin 13.6 g/dL, platelet count 1.9 lakhs/cmm and random blood glucose 160mg/dL. Blood urea, creatinine were within normal limits. Serum electrolytes revealed hyponatremia with Sodium of 123 mmol/L. The patient subsequently had high fever spikes. Dengue NS1Ag and IgM was negative, ICT kit test for Malaria was negative. RTPCR for COVID 19 was negative. Blood, urine,

RTA and bed sore cultures were sent and repeated which were unsuccessful in isolating any organism. As the clinical findings were not correlating with the findings on neuroimaging, MRI Brain was done. Area of T2/ FLAIR hyperintensity involving the left anterior and medial temporal lobe (including the insular cortex) with restricted diffusivity on DWI was noted suggestive of viral encephalitis (HSV) . Chronic small vessel ischaemic changes were also noted.



Neurophysician's opinion was sought and a lumbar puncture was performed as advised in view of subsequently noted nuchal rigidity. The patient was empirically started on injectable antibiotics and injectable Acyclovir considering the possibility of viral encephalitis. The CSF fluid was clear in appearance with microscopy showing lymphocytes 250/cmm. CSF biochemical analysis revealed mildly elevated proteins of 69mg/dL, low glucose of 99mg/dL for corresponding RBSL of 189mg/dL and chloride 109mmol/L and ADA was normal. Gram stain microscopy testing was negative. CSF CBNAAT was negative for Mycobacterium tuberculosis. Findings were consistent with viral encephalitis. CSF culture showed growth of Acinetobacter species sensitive

to Piperacillin+Tazobactam, Cefoperazone+Sulbactam, Imipenem, Meropenem, Amikacin, Colistin, Chloramphenicol, Nalidixic acid, Ciprofloxacin and Tigecycline. A repeat lumbar puncture done 4 days later was sent to a higher laboratory which again showed growth of Acinetobacter baumannii which was sensitive to Cefoperazone sulbactam, Gentamicin, Tigecycline, Minocycline, Colistin, Trimethoprim/Sulfamethoxazole and intermediately sensitive to Levofloxacin, Meropenem and Imipenem. CSF for HSV PCR was negative. Hence the clinical diagnosis of viral encephalitis with secondary Acinetobacter baumannii meningitis was made.



The patient was then started on Meropenem and Acyclovir was later discontinued. The patient was started on Colistin in view of persistent fever and after this became afebrile. However despite the full course of antibiotics, the patient continued to remain aphasic and had developed spasticity of all limbs. Hence injectable Acyclovir was restarted and continued for its full course of 14 days with regular monitoring of renal parameters. The patient was given regular physiotherapy and occupational therapy. At the end of treatment, considerable clinical improvement was noted with improvement of aphasia and spasticity.

III. DISCUSSION

To our knowledge, this is the first reported case of community-acquired *A. baumannii* meningitis in India. *A. baumannii* is a well-established meningeal pathogen in the neurosurgical setting but has been infrequently described as a cause of primary de novo meningitis. *A. baumannii* has been documented as a cause of pseudomeningitis (Cunha et al., 1999) but our patient's CSF showed clear evidence of bacterial meningitis. The negative Gram stain we attribute to the marked pleocytosis and heavily proteinaceous nature, which may have obscured the bacilli. Our case is in keeping with the clinical scenario of the other cases, where fever and a disturbed level of consciousness were predominant features. Furthermore, the antibiotic susceptibility profile was atypical for a nosocomial strain of *A. baumannii*, a feature consistent with other reported cases. *A. baumannii* is generally considered an opportunistic nosocomial pathogen and there is debate as to its mechanisms of pathogenicity and

virulence. The epidemiological profile suggests that it is of low virulence and disease is dependent on significant host immunological impairment.

Comorbidities such as chronic obstructive pulmonary disease, renal disease and diabetes mellitus are predisposing factors for *Acinetobacter* infections. Interestingly, heavy smoking and excessive alcohol consumption were also associated with increased risk of disease. Our patient's clinical presentation is unique and presented a diagnostic challenge. MRI and CSF studies markedly aided us in our diagnosis.

Attempts to characterize the epidemiology of community strains of *A. baumannii* suggest that the community may serve as a potential reservoir for both nosocomial and community-acquired infections. As highlighted by a previous study, the more interesting question is whether hospital strains that disseminate into the community serve as a potential reservoir for community-acquired infections. *A. baumannii* is capable of prolonged survival in the environment, and, with increasing dissemination of the organism into the community via healthcare-associated infection, it is feasible that *A. baumannii* will now adapt to the hostile environment of a host with an abnormal immune response. It is foreseeable that this highly adaptable organism may soon evolve into a significant community pathogen.

Unlike the *Acinetobacter* strains found in nosocomial infections, the strain of *Acinetobacter* meningitis in the community-acquired cases did not show resistance to multiple antibiotics. The treatment of *Acinetobacter* meningitis is usually at



least three weeks. The response should be assessed clinically and with repeat CSF cultures.³ Most adult patients with community-acquired *Acinetobacter* meningitis can be saved by timely therapy with appropriate antibiotics before deterioration of the systemic condition and impairment of consciousness.⁴

REFERENCES

- [1]. Kamath SA, Shah SN. API TEXTBOOK OF MEDICINE. 11th ed. New Delhi: CBS: 2019. 179 p.
- [2]. Lowman W, Kalk T, Menezes CN, John MA, Grobusch MP. A case of community-acquired *Acinetobacter baumannii* meningitis - has the threat moved beyond the hospital? *J Med Microbiol*. 2008 May;57(Pt 5):676-678. doi: 10.1099/jmm.0.47781-0. PMID: 18436607.
- [3]. Zeina A Kanafani, Souha S Kanj. *Acinetobacter* infection: Treatment and prevention. UpToDate.
- [4]. Chang WN, Lu CH, Huang CR, Chuang YC. Community-acquired *Acinetobacter* meningitis in adults. *Infection*. 2000 Nov-Dec;28(6):395-7. doi: 10.1007/s150100070013. PMID: 11139162.
- [5]. Saema Said; Michael Kang, Viral Encephalitis; StatPearls [Internet]. Jan 2021